In Context
Glioblastoma (GBM) is the most aggressive form of brain cancer. Even with surgical resection and radiotherapy, tumour cells remain at the resection margins and continue to infiltrate surrounding tissue. Batea Oncology developed GlioHook, a Class III implantable device, to improve survival rates in these patients.
Perdigó Medical designed and executed a complete mechanical characterisation and accelerated ageing for GlioHook, delivering a submission-ready test report.